Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

KARADAĞ, ÖMER; DALKILIÇ, HÜSEYİN; AYAN, GİZEM; KÜÇÜKŞAHİN, ORHAN; KAŞİFOĞLU, TİMUÇİN; Yilmaz, Neslihan; KOCA, SÜLEYMAN; YAZISIZ, VELİ; Erten, Pinar; Sayarlioglu, Mehmet; TERZİOĞLU, MUSTAFA; ERTEN, ŞÜKRAN; KALYONCU, UMUT

doi:10.1007/s10067-021-05893-3

Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

KARADAĞ Ö., DALKILIÇ H. E., AYAN G., KÜÇÜKŞAHİN O., KAŞİFOĞLU T., Yilmaz N., ...More

CLINICAL RHEUMATOLOGY, vol.41, no.1, pp.85-94, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 41 Issue: 1
Publication Date: 2022
Doi Number: 10.1007/s10067-021-05893-3
Journal Name: CLINICAL RHEUMATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.85-94
Keywords: Anti-TNF, ACR20/50/70, DAPSA28, DAS28, Psoriatic arthritis, Work disability, CERTOLIZUMAB PEGOL, CLINICAL-RESPONSE, DISEASE-ACTIVITY, DOUBLE-BLIND, PHASE-III, GOLIMUMAB, SAFETY, TRIAL, MULTICENTER, ETANERCEPT
Bursa Uludag University Affiliated: Yes

Abstract

Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.